S&P 500   3,214.73 (+0.54%)
DOW   26,747.73 (+0.39%)
QQQ   259.49 (-0.34%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,214.73 (+0.54%)
DOW   26,747.73 (+0.39%)
QQQ   259.49 (-0.34%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,214.73 (+0.54%)
DOW   26,747.73 (+0.39%)
QQQ   259.49 (-0.34%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,214.73 (+0.54%)
DOW   26,747.73 (+0.39%)
QQQ   259.49 (-0.34%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:IMNPImmune Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume12.29 million shs
Market Capitalization$8.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Read More
Immune Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMNP
Previous SymbolOTCMKTS:EPCT
CUSIPN/A
Phone201-464-2677

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$8.14 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMNP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter.

Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) announced its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.05. View Immune Pharmaceuticals' earnings history.

Has Immune Pharmaceuticals been receiving favorable news coverage?

Press coverage about IMNP stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immune Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news about Immune Pharmaceuticals.

Who are some of Immune Pharmaceuticals' key competitors?

What other stocks do shareholders of Immune Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), CytRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Novavax (NVAX), DryShips (DRYS), Heat Biologics (HTBX) and Molecular Templates (MTEM).

Who are Immune Pharmaceuticals' key executives?

Immune Pharmaceuticals' management team includes the following people:
  • Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
  • Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
  • Mr. Christine J. Petraglia, Director of Investor Relations
  • Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
  • Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How big of a company is Immune Pharmaceuticals?

Immune Pharmaceuticals has a market capitalization of $0.00.

What is Immune Pharmaceuticals' official website?

The official website for Immune Pharmaceuticals is www.immunepharmaceuticals.com.

How can I contact Immune Pharmaceuticals?

Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.